EWA LLC’s Vivos Therapeutics VVOS Stock Holding History

EWA LLC’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,464	Closed	-$29.8K	–	233
2025 Q1	$29.8K	Buy	+10,464	New	+$41.1K	0.01%	177

Other funds holding VVOS

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

EWA LLC's VVOS Position: Q2 2025 in Review

EWA LLC sold out of Vivos Therapeutics (VVOS) in Q2 2025, closing a stake of 10,464 shares — an estimated $29.8K sold.

EWA LLC first reported a position in VVOS in Q1 2025 and held it in 1 quarter. The position peaked at $29.8K in Q1 2025. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2025.

EWA LLC reported no remaining Vivos Therapeutics position as of Q2 2025 after selling out during the quarter.
EWA LLC sold 10,464 Vivos Therapeutics shares in Q2 2025, an estimated $29.8K.
EWA LLC first reported a position in Vivos Therapeutics in Q1 2025 and held it in 1 quarter.
EWA LLC's Vivos Therapeutics position peaked at $29.8K in Q1 2025.
19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2025.

Based on EWA LLC's 13F filing for Q2 2025, filed 18 Jul 2025.